Welcome to our dedicated page for Xencor news (Ticker: XNCR), a resource for investors and traders seeking the latest updates and insights on Xencor stock.
Xencor, Inc. develops engineered antibody therapeutics for cancer and autoimmune diseases using its XmAb technology platform and related antibody-engineering formats. News about XNCR commonly covers clinical and preclinical updates for XmAb drug candidates, including TL1A programs such as XmAb942 and XmAb412, T-cell engaging bispecific antibodies such as XmAb819 and XmAb541, and presentations of data at medical meetings.
Recurring company updates also include quarterly financial results, research-and-development priorities, collaboration and licensing activity, intellectual-property developments tied to Xtend Fc domain technology, and royalty matters involving partner-marketed medicines such as Ultomiris.
Xencor, Inc. (NASDAQ: XNCR) announced four new XmAb® programs for treating autoimmune diseases and provided updates on early-stage oncology programs. Key highlights include:
1. XmAb942: Phase 1 study for IBD to start Q4 2024, with data expected H1 2025.
2. Plamotamab (CD20 x CD3) and XmAb657 (CD19 x CD3): To be evaluated for autoimmune diseases, with studies starting in 2025.
3. XmAb819 (ENPP3 x CD3): Showing encouraging clinical activity in advanced clear cell renal cell carcinoma.
4. XmAb808 (B7-H3 x CD28): Demonstrating PSA declines in metastatic castration-resistant prostate cancer patients.
The company aims to leverage its protein engineering strengths to increase clinical success opportunities.
Xencor (NASDAQ: XNCR), a clinical-stage biopharmaceutical company, has announced a Research & Development Webcast and Conference Call scheduled for Monday, September 9, 2024, at 8:00 a.m. ET. The event will introduce new XmAb® programs for treating autoimmune diseases and provide updates on oncology programs, including:
- XmAb819 (ENPP3 x CD3) for advanced clear cell renal cell carcinoma
- XmAb808 (B7-H3 x CD28) for advanced solid tumors
The webcast can be accessed through the Investors section of Xencor's website. A recording will be available for at least 30 days after the event.
Xencor (NASDAQ:XNCR) reported Q2 2024 financial results and provided updates on its clinical-stage programs. Key highlights include:
- Cash position of $585.0 million as of June 30, 2024
- Q2 2024 revenues of $17.0 million, down from $45.5 million in Q2 2023
- Net loss of $66.0 million ($1.07 per share) in Q2 2024
- Advancing clinical trials for XmAb819, XmAb808, and XmAb541
- Regained worldwide rights to plamotamab
- Expects to end 2024 with $475-$525 million in cash, funding operations into 2027
The company continues to focus on developing bispecific T-cell engagers and other XmAb candidates, with plans to announce new clinical development candidates in the coming months.
Xencor (NASDAQ: XNCR) announced it will regain exclusive worldwide rights to plamotamab, a CD20 x CD3 bispecific T-cell engager, after Janssen Biotech terminated its rights under their collaboration agreement. Xencor had advanced plamotamab through Phase 1 clinical trials targeting hematologic cancers. Despite Janssen's withdrawal, it retains rights to develop and commercialize other B-cell targeting CD28 bispecific antibodies, JNJ-9401 and JNJ-1493, which are in Phase 1 clinical trials for prostate cancer and B-cell malignancies respectively.
Xencor emphasizes that plamotamab is Phase 2 ready and subcutaneously administered, highlighting its potential to address unmet medical needs. The company remains eligible for milestone payments and royalties from Janssen's ongoing projects and has the option to co-fund development costs for increased royalty benefits.
Xencor, a clinical-stage biopharmaceutical company, reported financial results for the first quarter ended March 31, 2024, focusing on bispecific T cell engagers for cancer treatment. Recent highlights include the advancement of multiple oncology programs, FDA approval of Ultomiris, and positive results in malaria prevention. The company appointed a new CFO and provided financial guidance with a cash balance of $646.7 million as of March 31, 2024. Despite a decrease in revenues and an increased net loss compared to the previous year, Xencor remains well-funded.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.